Combined taxane, platinum, and cetuximab as a first‐line treatment for recurrent/metastatic head and neck squamous cell carcinoma: Retrospective study
- 1 August 2022
- journal article
- research article
- Published by Wiley in Head & Neck
- Vol. 44 (9) , 2040-2045
Abstract
Background: There is limited evidence supporting the use of taxane‐based chemotherapy combined with cetuximab to treat recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). This retrospective study aimed to explore treatment efficacy and safety in a first‐line setting.Methods: Fifty‐nine patients received ≤6 cycles of combined cetuximab, platinum compounds, and taxane (median follow‐up, 352 days). Kaplan–Meier survival curves were constructed.Results: The median patient age was 54 years (23–75 years; 50 males and 9 females). The most common distant metastatic site was the lung. Patients received ≥2 cycles chemotherapy (33 [55.9%] received cetuximab, paclitaxel, and carboplatin; 21 [35.5%] received cetuximab maintenance; median progression‐free survival, 7 months; overall survival, 12 months). The most common hematological toxicity was Grade 3 or 4 neutropenia, which was successfully managed through growth‐stimulating factors and dose modifications. No treatment‐associated deaths occurred.Conclusions: Combined cetuximab, platinum, and taxane is effective and tolerable in R/M HNSCC.Keywords
This publication has 15 references indexed in Scilit:
- Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 studyThe Lancet, 2019
- A comparison of weekly paclitaxel and cetuximab with the EXTREME regimen in the treatment of recurrent/metastatic squamous cell head and neck carcinomaOral Oncology, 2017
- Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and NeckNew England Journal of Medicine, 2016
- Global and National Burden of Diseases and Injuries Among Children and Adolescents Between 1990 and 2013JAMA Pediatrics, 2016
- Current Treatment Options for Recurrent or Metastatic Head and Neck Squamous Cell CarcinomaJournal of Clinical Oncology, 2015
- Cetuximab, docetaxel, and cisplatin as first-line treatment in patients with recurrent or metastatic head and neck squamous cell carcinoma: a multicenter, phase II GORTEC studyAnnals of Oncology, 2015
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- Platinum-Based Chemotherapy plus Cetuximab in Head and Neck CancerNew England Journal of Medicine, 2008
- Antibody‐dependent cellular cytotoxicity of cetuximab against tumor cells with wild‐type or mutant epidermal growth factor receptorCancer Science, 2007
- Structural basis for inhibition of the epidermal growth factor receptor by cetuximabCancer Cell, 2005